Impact Therapeutics Announces the Closing of Series D1 Financing

The Series D1 funding was raised by Impact Therapeutics, an undisclosed amount for a biopharmaceutical firm based in Shanghai, China.

The round was led by Dingxin Capital, CCBT, C&D EMERGING CAPITAL, Bestride, Exome Asset Management with participation from LAV, China Summit, and Yuexiu.

The funds will be used by the company to speed up the development of its synthetic limbality programs.

Led by CEO Dr. Jun Bao, Impact Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. The company boasts one of the largest global DNA damage responses (DDR), pipelines of new drug candidates. It is currently expanding its reach to include other synthetic lethality targets. IMPACT products include PARP inhibitor (Senaparib/ IMP4297), wee1 inhibitor(IMP7068), and ATR inhibitor(IMP9064). There are also other DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China.

 

Get latest news from African Startup ecosystem

Latest stories

You might also like...